First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Basit Öğe Kaydı
dc.authoridSadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorscopusidSadettin Kılıçkap / 8665552100en_US
dc.authorwosidSadettin Kılıçkap / AAP-3732-2021en_US
dc.contributor.authorAktürk Esen, Selin
dc.contributor.authorErgün, Yakup
dc.contributor.authorErol, Cihan
dc.contributor.authorArıkan, Rukiye
dc.contributor.authorEr, Muhammed Muhiddin
dc.date.accessioned2022-11-08T13:16:53Z
dc.date.available2022-11-08T13:16:53Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Hastaneen_US
dc.description.abstractFluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which plati-num-based treatment should be preferred. This study aimed to compare the treatment response and survival characteristics of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer who received f luorouracil, oxaliplatin, and leucovo-rin (mFOLFOX)+trastuzumab or cisplatin and f luorouracil (CF)+trastuzumab as first-line therapy. It was a multicenter, retrospective study of the Turkish Oncology Group, which included 243 patients from 21 oncology centers. There were 113 patients in the mFOLF-OX+trastuzumab arm and 130 patients in the CF+trastuzumab arm. The median age was 62 years in the mFOLFOX+trastuzumab arm and 61 years in the CF+trastuzumab arm (p = 0.495). About 81.4% of patients in the mFOLFOX+trastuzumab arm and 83.1% in the CF+trastuzumab arm had gastric tumor localization (p = 0.735). The median progression-free survival (PFS) was significantly higher in the mFOLFOX+trastuzumab arm (9.4 months vs. 7.3 months, p = 0.024). The median overall survival (OS) was similar in both groups (18.4 months vs. 15.1 months, p = 0.640). Maintenance trastuzumab was continued after chemotherapy in 101 patients. In this subgroup, the median OS was 23.3 months and the median PFS was 13.3 months. In conclusion, mFOLFOX+trastuzumab is similar to CF+trastuzumab in terms of the median OS, but it is more effective in terms of the median PFS in the first-line treatment of HER2-positive metastatic gastric and GEJ cancer. The choice of treatment should be made by considering the prominent toxicity findings of the chemotherapy regimens.en_US
dc.identifier.citationEsen, S. A., Ergun, Y., Erol, C., Arikan, R., Er, M. M., Atci, M. M., . . . Uncu, D. (2022). First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer. Bosnian Journal of Basic Medical Sciences, 22(5), 818-825. doi:10.17305/bjbms.2021.7069en_US
dc.identifier.doi10.17305/bjbms.2021.7069en_US
dc.identifier.endpage825en_US
dc.identifier.issue5en_US
dc.identifier.scopus2-s2.0-85138273094en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage818en_US
dc.identifier.urihttps://doi.org/10.17305/bjbms.2021.7069
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3261
dc.identifier.volume22en_US
dc.identifier.wosWOS:000883458600005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherAssociation of Basic Medical Sciences of FBIHen_US
dc.relation.ispartofBosnian Journal of Basic Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCFen_US
dc.subjectFOLFOXen_US
dc.subjectGastric Canceren_US
dc.subjectGastroesophageal Junction Canceren_US
dc.subjectTrastuzumaben_US
dc.titleFirst-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction canceren_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
7069-Article Text-45445-3-10-20220914.pdf
Boyut:
511.61 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
İSÜ Hastaneleri Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu